Crescendo Bioscience said this week that it has received accreditation for its laboratory from the Commission on Laboratory Accreditation of the College of American Pathologists.
The accreditation offers further validation of the company's CLIA lab facility and its 12 protein Vectra DA test that it runs out of that facility, William Hagstrom, Crescendo's president and CEO said in a statement.
CAP accreditation involves examination of a laboratory’s records and quality control procedures for the preceding two years as well as examination of staff qualifications, laboratory equipment, safety programs and records, and overall laboratory management.
The U.S. government recognizes the CAP Laboratory Accreditation Program as being equal-to or more-stringent-than the government’s own inspection program, Crescendo said.
The CAP accreditation follows Crescendo's receipt in April of approval for its CLIA lab from the New York Department of Health's Clinical Laboratory Evaluation Program. With that approval, Vectra DA is now available in all 50 states.